메뉴 건너뛰기




Volumn 19, Issue 10, 2017, Pages 1284-1293

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

(20)  Ferreira, João Pedro a,b   Rossignol, Patrick a   Machu, Jean Loup a   Sharma, Abhinav c,d   Girerd, Nicolas a   Anker, Stefan D e   Cleland, John G f   Dickstein, Kenneth g,h   Filippatos, Gerasimos i   Hillege, Hans L j   Lang, Chim C k   ter Maaten, Jozine M j,l   Metra, Marco m   Ng, Leong n   Ponikowski, Piotr o   Samani, Nilesh J n   van Veldhuisen, Dirk J j   Zwinderman, Aeilko H p   Voors, Adriaan j   Zannad, Faiez a  


Author keywords

Adherence; Mineralocorticoid receptor antagonists; Observational; Prescription; Real life

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SODIUM;

EID: 85020174728     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.900     Document Type: Article
Times cited : (82)

References (50)
  • 1
    • 0033517302 scopus 로고    scopus 로고
    • The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
    • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
    • (1999) N Engl J Med , vol.341 , pp. 709-717
    • Pitt, B.1    Zannad, F.2    Remme, W.J.3    Cody, R.4    Castaigne, A.5    Perez, A.6    Palensky, J.7    Wittes, J.8
  • 3
  • 6
    • 84920024290 scopus 로고    scopus 로고
    • Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries
    • Rossignol P, Zannad F, Pitt B. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. Int J Cardiol 2014;177:731–733.
    • (2014) Int J Cardiol , vol.177 , pp. 731-733
    • Rossignol, P.1    Zannad, F.2    Pitt, B.3
  • 7
    • 84989842026 scopus 로고    scopus 로고
    • Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia
    • Pitt B, Rossignol P. Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacol Res 2016;118:2–4.
    • (2016) Pharmacol Res , vol.118 , pp. 2-4
    • Pitt, B.1    Rossignol, P.2
  • 8
    • 78649437710 scopus 로고    scopus 로고
    • Heart failure guidelines, performance measures, and the practice of medicine: mind the gap
    • Ghali JK, Massie BM, Mann DL, Rich MW. Heart failure guidelines, performance measures, and the practice of medicine: mind the gap. J Am Coll Cardiol 2010;56:2077–2080.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 2077-2080
    • Ghali, J.K.1    Massie, B.M.2    Mann, D.L.3    Rich, M.W.4
  • 9
    • 84886023778 scopus 로고    scopus 로고
    • Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
    • Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013;62:1585–1593.
    • (2013) J Am Coll Cardiol , vol.62 , pp. 1585-1593
    • Eschalier, R.1    McMurray, J.J.2    Swedberg, K.3    van Veldhuisen, D.J.4    Krum, H.5    Pocock, S.J.6    Shi, H.7    Vincent, J.8    Rossignol, P.9    Zannad, F.10    Pitt, B.11
  • 10
    • 84899500566 scopus 로고    scopus 로고
    • Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study
    • Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol 2014;173:380–387.
    • (2014) Int J Cardiol , vol.173 , pp. 380-387
    • Rossignol, P.1    Dobre, D.2    Gregory, D.3    Massaro, J.4    Kiernan, M.5    Konstam, M.A.6    Zannad, F.7
  • 11
    • 84868574835 scopus 로고    scopus 로고
    • Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)
    • Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD; RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012;60:2082–2089.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 2082-2089
    • Vardeny, O.1    Wu, D.H.2    Desai, A.3    Rossignol, P.4    Zannad, F.5    Pitt, B.6    Solomon, S.D.7
  • 12
    • 84907389177 scopus 로고    scopus 로고
    • Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist
    • Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7:573–579.
    • (2014) Circ Heart Fail , vol.7 , pp. 573-579
    • Vardeny, O.1    Claggett, B.2    Anand, I.3    Rossignol, P.4    Desai, A.S.5    Zannad, F.6    Pitt, B.7    Solomon, S.D.8
  • 14
    • 85006197330 scopus 로고    scopus 로고
    • Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure
    • Dev S, Lacy ME, Masoudi FA, Wu WC. Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure. J Am Heart Assoc 2015;4:e002268.
    • (2015) J Am Heart Assoc , vol.4
    • Dev, S.1    Lacy, M.E.2    Masoudi, F.A.3    Wu, W.C.4
  • 15
    • 79956213148 scopus 로고    scopus 로고
    • Use, tolerability and compliance of spironolactone in the treatment of heart failure
    • Lachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 2011;11:4.
    • (2011) BMC Clin Pharmacol , vol.11 , pp. 4
    • Lachaine, J.1    Beauchemin, C.2    Ramos, E.3
  • 16
    • 77957763788 scopus 로고    scopus 로고
    • Adherence to aldosterone-blocking agents in patients with heart failure
    • Margolis J, Gerber RA, Roberts C, Gheorghiade M. Adherence to aldosterone-blocking agents in patients with heart failure. Am J Ther 2010;17:446–454.
    • (2010) Am J Ther , vol.17 , pp. 446-454
    • Margolis, J.1    Gerber, R.A.2    Roberts, C.3    Gheorghiade, M.4
  • 21
    • 53249090182 scopus 로고    scopus 로고
    • ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
    • Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–2442.
    • (2008) Eur Heart J , vol.29 , pp. 2388-2442
    • Dickstein, K.1    Cohen-Solal, A.2    Filippatos, G.3    McMurray, J.J.4    Ponikowski, P.5    Poole-Wilson, P.A.6    Strömberg, A.7    van Veldhuisen, D.J.8    Atar, D.9    Hoes, A.W.10    Keren, A.11    Mebazaa, A.12    Nieminen, M.13    Priori, S.G.14    Swedberg, K.15
  • 27
    • 85017459818 scopus 로고    scopus 로고
    • Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
    • 19974–986
    • Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail 2017;19:974–986.
    • (2017) Eur J Heart Fail
    • Ferreira, J.P.1    Mentz, R.J.2    Pizard, A.3    Pitt, B.4    Zannad, F.5
  • 30
    • 21844459736 scopus 로고    scopus 로고
    • Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001
    • Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001. Circulation 2005;112:39–47.
    • (2005) Circulation , vol.112 , pp. 39-47
    • Masoudi, F.A.1    Gross, C.P.2    Wang, Y.3    Rathore, S.S.4    Havranek, E.P.5    Foody, J.M.6    Krumholz, H.M.7
  • 33
    • 0037438820 scopus 로고    scopus 로고
    • Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
    • Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211–214.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 211-214
    • Bozkurt, B.1    Agoston, I.2    Knowlton, A.A.3
  • 34
    • 33645824752 scopus 로고    scopus 로고
    • Use and side-effect profile of spironolactone in a private cardiologist's practice
    • Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006;29:149–153.
    • (2006) Clin Cardiol , vol.29 , pp. 149-153
    • Williams, E.M.1    Katholi, R.E.2    Karambelas, M.R.3
  • 35
    • 24044466543 scopus 로고    scopus 로고
    • The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure
    • Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845–849.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 845-849
    • Shah, K.B.1    Rao, K.2    Sawyer, R.3    Gottlieb, S.S.4
  • 36
    • 84946761083 scopus 로고    scopus 로고
    • Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure
    • Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 2015;314:1973–1975.
    • (2015) JAMA , vol.314 , pp. 1973-1975
    • Cooper, L.B.1    Hammill, B.G.2    Peterson, E.D.3    Pitt, B.4    Maciejewski, M.L.5    Curtis, L.H.6    Hernandez, A.F.7
  • 37
    • 0034727695 scopus 로고    scopus 로고
    • Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators
    • Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700–2706.
    • (2000) Circulation , vol.102 , pp. 2700-2706
    • Zannad, F.1    Alla, F.2    Dousset, B.3    Perez, A.4    Pitt, B.5
  • 38
    • 34250818053 scopus 로고    scopus 로고
    • Drug insight: aldosterone-receptor antagonists in heart failure—the journey continues
    • Kalidindi SR, Tang WH, Francis GS. Drug insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nat Clin Pract Cardiovasc Med 2007;4:368–378.
    • (2007) Nat Clin Pract Cardiovasc Med , vol.4 , pp. 368-378
    • Kalidindi, S.R.1    Tang, W.H.2    Francis, G.S.3
  • 41
    • 53249122867 scopus 로고    scopus 로고
    • Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey
    • Erhardt L, Komajda M, Hobbs FD, Soler-Soler J. Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey. Eur J Heart Fail 2008;10:1020–1025.
    • (2008) Eur J Heart Fail , vol.10 , pp. 1020-1025
    • Erhardt, L.1    Komajda, M.2    Hobbs, F.D.3    Soler-Soler, J.4
  • 43
    • 84896109810 scopus 로고    scopus 로고
    • Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
    • Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:51–58.
    • (2014) Circ Heart Fail , vol.7 , pp. 51-58
    • Rossignol, P.1    Dobre, D.2    McMurray, J.J.3    Swedberg, K.4    Krum, H.5    van Veldhuisen, D.J.6    Shi, H.7    Messig, M.8    Vincent, J.9    Girerd, N.10    Bakris, G.11    Pitt, B.12    Zannad, F.13
  • 46
    • 85011968147 scopus 로고    scopus 로고
    • Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors
    • Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl):S212–220.
    • (2015) Am J Manag Care , vol.21 , Issue.11 , pp. S212-220
    • Epstein, M.1    Reaven, N.L.2    Funk, S.E.3    McGaughey, K.J.4    Oestreicher, N.5    Knispel, J.6
  • 48
    • 84886283448 scopus 로고    scopus 로고
    • Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison
    • Agrinier N, Altieri C, Alla F, Jay N, Dobre D, Thilly N, Zannad F. Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison. Int J Cardiol 2013;168:3652–3658.
    • (2013) Int J Cardiol , vol.168 , pp. 3652-3658
    • Agrinier, N.1    Altieri, C.2    Alla, F.3    Jay, N.4    Dobre, D.5    Thilly, N.6    Zannad, F.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.